Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018

Jun 14, 2018

Rexahn Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

Jun 4, 2018

Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage

May 15, 2018

Rexahn Reports First Quarter 2018 Financial Results

May 7, 2018

Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2018

Rexahn Pharmaceuticals to Present at Two Upcoming Conferences

Mar 13, 2018

Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results

Mar 12, 2018

Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting

Feb 12, 2018

Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma

Feb 8, 2018

Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting

Feb 5, 2018